AI Engines For more Details: Perplexity Kagi Labs You
Analgesic Effects: Thiorphan's inhibition of NEP can lead to increased levels of endogenous opioid peptides such as enkephalins. Enkephalins are neurotransmitters that bind to opioid receptors in the brain and spinal cord, modulating pain perception. Therefore, thiorphan may exhibit analgesic (pain-relieving) effects by enhancing the activity of endogenous opioids.
Neurotransmitter Modulation: Substance P is a neuropeptide involved in pain transmission and modulation. By inhibiting NEP, thiorphan can increase substance P levels, potentially affecting nociceptive signaling and neurogenic inflammation.
Cardiovascular Effects: NEP is involved in the degradation of atrial natriuretic peptide (ANP), a hormone that regulates blood pressure and fluid balance. Thiorphan's inhibition of NEP can lead to increased ANP levels, resulting in vasodilation, natriuresis (excretion of sodium in urine), and diuresis (increased urine production). These effects may contribute to the regulation of blood pressure and fluid volume.
Potential Therapeutic Uses: Due to its effects on pain perception and cardiovascular function, thiorphan has been studied for various therapeutic applications. It has been investigated as a potential analgesic agent for the treatment of acute and chronic pain conditions. Additionally, thiorphan's ability to modulate ANP levels may have implications for the management of hypertension, heart failure, and other cardiovascular disorders.
Side Effects and Adverse Reactions: Like any medication, thiorphan may cause side effects and adverse reactions. Common side effects may include gastrointestinal disturbances, dizziness, headache, and fatigue. In some cases, thiorphan may interact with other medications or substances, so it's essential to consult a healthcare professional before use, especially if you have any underlying medical conditions or are taking other medications.
Research and Development: While thiorphan has shown promise in preclinical studies and experimental models, further research is needed to determine its safety and efficacy in clinical settings. Clinical trials evaluating thiorphan's potential therapeutic benefits and optimal dosing regimens are necessary to validate its use in various medical conditions.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 0.3 | 0.3 | |
| Allergic Rhinitis (Hay Fever) | 0.1 | 0.1 | |
| Allergies | 0.4 | 0.3 | 0.33 |
| Alzheimer's disease | 0.6 | 0.2 | 2 |
| Ankylosing spondylitis | 0.4 | -0.4 | |
| Antiphospholipid syndrome (APS) | 0.3 | -0.3 | |
| Asthma | 0.3 | 0.3 | |
| Atherosclerosis | 0.3 | 0.3 | |
| Atrial fibrillation | 0.3 | -0.3 | |
| Autism | 0.6 | 0.6 | 0 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| Biofilm | 0.1 | 0.1 | |
| Bipolar Disorder | 0.3 | 0.3 | |
| Breast Cancer | 0 | 0 | |
| Cancer (General) | 0.3 | 0.3 | |
| Carcinoma | 0.6 | 0.6 | |
| Celiac Disease | 0.3 | -0.3 | |
| Chronic Fatigue Syndrome | 0.6 | 0.2 | 2 |
| Chronic Kidney Disease | 0.1 | 0.3 | -2 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.3 | 0 |
| Colorectal Cancer | 0.6 | 0.6 | |
| Coronary artery disease | 0.1 | 0.1 | |
| COVID-19 | 0.4 | 0.2 | 1 |
| Crohn's Disease | 0.7 | 0.3 | 1.33 |
| deep vein thrombosis | 0 | 0 | |
| Denture Wearers Oral Shifts | 0 | 0 | |
| Depression | 0.8 | 0.8 | |
| Eczema | 0.4 | 0.4 | |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 0.3 | 0.3 | |
| erectile dysfunction | 0.5 | 0.5 | |
| Fibromyalgia | 0.1 | 0.1 | |
| gallstone disease (gsd) | 0.1 | 0.3 | -2 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | |
| Generalized anxiety disorder | 0.4 | 0.4 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.3 | 0.3 | 0 |
| Heart Failure | 0.1 | 0.1 | |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.3 | -0.3 | |
| IgA nephropathy (IgAN) | 0.3 | 0.1 | 2 |
| Inflammatory Bowel Disease | 0.6 | 0.5 | 0.2 |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 0.1 | 0.1 | |
| Liver Cirrhosis | 0.6 | 0.6 | 0 |
| Long COVID | 0.7 | 0.6 | 0.17 |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0 | 0 | |
| ME/CFS with IBS | 0.2 | 0.2 | |
| ME/CFS without IBS | 0.1 | 0.1 | |
| Metabolic Syndrome | 0.9 | 0.6 | 0.5 |
| Mood Disorders | 0.8 | 0.8 | |
| Multiple Sclerosis | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 0.4 | |
| Obesity | 0.7 | 0.4 | 0.75 |
| obsessive-compulsive disorder | 0.1 | -0.1 | |
| Osteoarthritis | 0.2 | 0.2 | |
| pancreatic cancer | 0 | 0 | |
| Parkinson's Disease | 0.3 | 1 | -2.33 |
| Polycystic ovary syndrome | 0.4 | 0.3 | 0.33 |
| primary biliary cholangitis | 0.3 | -0.3 | |
| Primary sclerosing cholangitis | 0.3 | 0.1 | 2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.4 | 0.3 | 0.33 |
| Schizophrenia | 0.6 | 0.6 | |
| scoliosis | 0.3 | -0.3 | |
| Sleep Apnea | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.3 | |
| Systemic Lupus Erythematosus | 0.7 | 0.6 | 0.17 |
| Type 1 Diabetes | 0.3 | 0.3 | |
| Type 2 Diabetes | 0.9 | 0.3 | 2 |
| Ulcerative colitis | 0.1 | 0.3 | -2 |
| Unhealthy Ageing | 0.9 | 0.9 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
